Security key
74907L409
Quoin Pharmaceuticals, Ltd. - Ordinary Shares, no par value per share (QNRX)
CUSIP: 74907L409
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Ordinary Shares, no par value per share
- Total 13F shares
- 1,491
- Total 13F value
- $10,716
- Share change
- -1,046
- SEC-reported price per share
- $7.09
- Number of holders
- 4
- Value change
- -$9,379
- Number of buys
- 1
- Number of sells
- 4
- Shares outstanding
- 70,007,000
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
4
Top holders
4
QNRX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Quoin Pharmaceuticals, Ltd. SEC filings
Quoin Pharmaceuticals, Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74907L409
Recent filing periods:
Ownership snapshot
Top reported holders of QNRX - Quoin Pharmaceuticals, Ltd. - Ordinary Shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
9/10
Latest evidence
30 Jun 2025
13D/G
13F
3/4/5
Lead comparable stake: 5%
1 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 10 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
9 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
Denise P. Carter
4.9%
Michael Myers
4.9%
RHUMBLINE ADVISERS
0%
RAYMOND JAMES FINANCIAL INC
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$7,049,313
1,081,183 shares
|
$0 | 31 Mar 2025 |
| Denise P. Carter |
13D/G
Denise Carter
|
4.9%
|
$244,202
939,238 shares
|
+$82,374 | 27 Jan 2025 |
| Michael Myers |
13D/G
|
4.9%
|
$244,200
939,230 shares
|
+$82,331 | 27 Jan 2025 |
| RHUMBLINE ADVISERS |
13F
Company
|
0%
|
$11,448
1,242 shares
|
— | 30 Jun 2025 |
| RAYMOND JAMES FINANCIAL INC |
13F
Company
|
0%
|
$6,618
717 shares
|
— | 30 Jun 2025 |
| GAMMA Investing LLC |
13F
Company
|
0%
|
$2,215
240 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
1,491
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
20
Q3 2025 holders
4
Holder diff
-16
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend